|

HLX10 Clinical Trials

6 actively recruiting trials

No change since May 2026

Also known as: Serplulimab, serplulimab

Pipeline

Phase 2: 4Phase 3: 1Phase 2/3: 1

Top Sponsors

  • Shanghai Henlius Biotech3
  • Tianjin Medical University Cancer Institute and Hospital1
  • Tao Zhang1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer6
  • Resectable Esophageal Squamous Cell Carcinoma1
  • Liver Disease1
  • MSI-H Solid Malignant Tumor1
  • Total Neoadjuvant Therapy1

Other6 trials

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Phase 2/3
A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy
Phase 2
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
Phase 3
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Phase 2
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Phase 2
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.